
SEER CERTIFIED TUMOR REGISTRAR (CTR) OPERATIONS PRACTICE EXAM (SAMPLE)

STUDY GUIDE



SAMPLE STUDY GUIDE WITH LIMITED QUESTIONS

VISIT US ONLINE FOR THE FULL VERSION STUDY GUIDE

https://seerctroperations.examzify.com

Copyright © 2026 by Examzify - A Kaluba Technologies Inc. product.

ALL RIGHTS RESERVED.

No part of this book may be reproduced or transferred in any form or by any means, graphic, electronic, or mechanical, including photocopying, recording, web distribution, taping, or by any information storage retrieval system, without the written permission of the author.

Notice: Examzify makes every reasonable effort to obtain accurate, complete, and timely information about this product from reliable sources.

SAMPLE

Table of Contents

Copyright 1

Table of Contents 2

Introduction 3

How to Use This Guide 4

Questions 5

Answers 8

Explanations 10

Next Steps 16

SAMPLE

Introduction

Preparing for a certification exam can feel overwhelming, but with the right tools, it becomes an opportunity to build confidence, sharpen your skills, and move one step closer to your goals. At Examzify, we believe that effective exam preparation isn't just about memorization, it's about understanding the material, identifying knowledge gaps, and building the test-taking strategies that lead to success.

This guide was designed to help you do exactly that.

Whether you're preparing for a licensing exam, professional certification, or entry-level qualification, this book offers structured practice to reinforce key concepts. You'll find a wide range of multiple-choice questions, each followed by clear explanations to help you understand not just the right answer, but why it's correct.

The content in this guide is based on real-world exam objectives and aligned with the types of questions and topics commonly found on official tests. It's ideal for learners who want to:

- Practice answering questions under realistic conditions,
- Improve accuracy and speed,
- Review explanations to strengthen weak areas, and
- Approach the exam with greater confidence.

We recommend using this book not as a stand-alone study tool, but alongside other resources like flashcards, textbooks, or hands-on training. For best results, we recommend working through each question, reflecting on the explanation provided, and revisiting the topics that challenge you most.

Remember: successful test preparation isn't about getting every question right the first time, it's about learning from your mistakes and improving over time. Stay focused, trust the process, and know that every page you turn brings you closer to success.

Let's begin.

SAMPLE

How to Use This Guide

This guide is designed to help you study more effectively and approach your exam with confidence. Whether you're reviewing for the first time or doing a final refresh, here's how to get the most out of your Examzify study guide:

1. Start with a Diagnostic Review

Skim through the questions to get a sense of what you know and what you need to focus on. Your goal is to identify knowledge gaps early.

2. Study in Short, Focused Sessions

Break your study time into manageable blocks (e.g. 30 – 45 minutes). Review a handful of questions, reflect on the explanations.

3. Learn from the Explanations

After answering a question, always read the explanation, even if you got it right. It reinforces key points, corrects misunderstandings, and teaches subtle distinctions between similar answers.

4. Track Your Progress

Use bookmarks or notes (if reading digitally) to mark difficult questions. Revisit these regularly and track improvements over time.

5. Simulate the Real Exam

Once you're comfortable, try taking a full set of questions without pausing. Set a timer and simulate test-day conditions to build confidence and time management skills.

6. Repeat and Review

Don't just study once, repetition builds retention. Re-attempt questions after a few days and revisit explanations to reinforce learning. Pair this guide with other Examzify tools like flashcards, and digital practice tests to strengthen your preparation across formats.

There's no single right way to study, but consistent, thoughtful effort always wins. Use this guide flexibly, adapt the tips above to fit your pace and learning style. You've got this!

SAMPLE

Questions

SAMPLE

1. Which of the following data points is NOT considered critical patient information?

A. Current address

B. Date of birth

C. Medical insurance provider

D. Vital status

2. What criterion does not affect the frequency and format of required cancer conferences?

A. Program category

B. The need for consultative services

C. The number of analytic cases seen annually at the facility

D. None of the above

3. To which agency do central registries report their data directly?

A. National Program of Cancer Registries (NPCR).

B. National Cancer Data Base (NCDB).

C. Both (a) and (b).

D. Neither (a) nor (b).

4. Neoadjuvant therapy is administered at what point in relation to surgery?

A. After surgery

B. Before surgery

C. During surgery

D. Only if surgery is not an option

5. When should updates to the ICD-9-CM and ICD-10-CM coding manuals typically take effect?

A. January

B. June

C. October

D. December

SAMPLE

6. Why is the transition to ICD-10-CM preferred over continuing with ICD-9-CM?

A. ICD-10-CM has a simpler structure

B. ICD-10-CM provides greater specificity and detail

C. ICD-10-CM is less expensive to implement

D. ICD-10-CM is the older system

7. What impact does an incomplete reportability list have on casefinding?

A. It ensures all cases are reported

B. It has no effect on casefinding procedures

C. It could lead to underreporting of cases

D. It guarantees accurate data collection

8. What is commonly used to help determine treatment and prognosis for non-small cell lung cancer?

A. ALK gene rearrangements

B. BRAF mutation V600E

C. CD20

D. EGFR mutation analysis

9. An important tumor identification field(s) is

A. Laterality

B. Vital status

C. Both (a) and (b)

D. Neither (a) nor (b)

10. Reportable diagnoses made in utero are reportable if the:

A. Pregnancy results in a live birth.

B. Diagnosis was confirmed prior to birth and the disease is not evident at birth due to regression.

C. Both (a) and (b)

D. Neither (a) nor (b)

SAMPLE

Answers

SAMPLE

1. C
2. D
3. A
4. B
5. C
6. B
7. C
8. D
9. A
10. C

SAMPLE

Explanations

SAMPLE

1. Which of the following data points is NOT considered critical patient information?

A. Current address

B. Date of birth

C. Medical insurance provider

D. Vital status

The correct answer indicates that the medical insurance provider is not considered critical patient information in the context of tumor registries and cancer data collection. Critical patient information typically includes data that directly impacts patient care and treatment outcomes, such as vital status, date of birth, and current address. Vital status is crucial as it indicates whether the patient is alive or deceased, which affects prognosis and treatment history. The date of birth is essential for determining the age of the patient, which can influence cancer risk and treatment responses. Current address is also important for follow-up purposes and understanding demographic patterns. In contrast, while knowing a patient's medical insurance provider may be relevant for billing and financial decisions, it does not directly contribute to clinical treatment protocols or outcomes in the same essential manner as the other data points. Therefore, it is not categorized as critical patient information within the scope of a tumor registry's focus on cancer data collection and patient management.

2. What criterion does not affect the frequency and format of required cancer conferences?

A. Program category

B. The need for consultative services

C. The number of analytic cases seen annually at the facility

D. None of the above

The frequency and format of required cancer conferences are influenced by specific criteria, such as the program category, the need for consultative services, and the number of analytic cases seen annually at the facility. Each of these factors plays a pivotal role in determining how often conferences are held and their structure. The program category outlines the type and scope of the cancer program, which can dictate the necessity for regular multidisciplinary team discussions. The need for consultative services is another crucial criterion, as facilities must convene conferences when there are complex cases that require expert input from various specialists. Additionally, the number of analytic cases affects how often these conferences occur; a higher volume of cases often necessitates more frequent meetings for thorough case reviews and treatment planning. Since all the options presented relate directly to the criteria that influence the regularity and organization of cancer conferences, selecting "None of the above" indicates an understanding that each of these choices reflects factors that indeed affect the operational aspects of cancer conferences. This demonstrates a comprehensive awareness of the operational dynamics within cancer treatment facilities and the importance of collaborative care in improving patient outcomes.

SAMPLE

3. To which agency do central registries report their data directly?

A. National Program of Cancer Registries (NPCR).

B. National Cancer Data Base (NCDB).

C. Both (a) and (b).

D. Neither (a) nor (b).

Central registries report their data directly to the National Program of Cancer Registries (NPCR), which is managed by the Centers for Disease Control and Prevention (CDC). The NPCR oversees the collection and management of cancer data from state cancer registries to ensure a comprehensive dataset that reflects cancer incidence across the United States. This oversight is crucial for public health surveillance, trend analysis, and the development of cancer control programs. In contrast, the National Cancer Data Base (NCDB) is a clinical database designed primarily for the purpose of quality improvement and cancer research. While both NPCR and NCDB play significant roles in cancer data collection and use, the NPCR is the agency specifically designated for direct reporting from central registries. As a result, the NPCR serves as the primary federal agency responsible for collecting cancer data from state registries, making the choice to report to NPCR essential for the nation's cancer epidemiology and surveillance efforts.

4. Neoadjuvant therapy is administered at what point in relation to surgery?

A. After surgery

B. Before surgery

C. During surgery

D. Only if surgery is not an option

Neoadjuvant therapy is specifically given before surgery with the aim of reducing the size of the tumor or eliminating metastatic disease, which can make surgical removal more successful or less extensive. This approach can also help assess how well the tumor responds to treatment, providing valuable information about its biology and behavior. Administering this therapy before surgery can sometimes lead to better surgical outcomes and ultimately improve the prognosis for patients. It's a strategic way to potentially shrink the tumor and make it operable, or to allow for a less invasive surgical approach.

5. When should updates to the ICD-9-CM and ICD-10-CM coding manuals typically take effect?

A. January

B. June

C. October

D. December

Updates to the ICD-9-CM and ICD-10-CM coding manuals typically take effect in October. This timing aligns with the annual updates that are made to the International Classification of Diseases (ICD) systems, which include changes in codes, guidelines, and instructions. The October implementation date allows healthcare providers, coders, and other stakeholders adequate time to prepare for the upcoming changes that will be reflected in the coding manuals. The annual updates are particularly important in reflecting new medical knowledge, changes in medical technology, and alterations in treatment protocols. By establishing a set update month, such as October, there is a standardized schedule that all healthcare organizations across the United States can follow, ensuring consistency in coding practices in the months leading up to and following the implementation of new or revised codes.

EXAMPLE

6. Why is the transition to ICD-10-CM preferred over continuing with ICD-9-CM?

A. ICD-10-CM has a simpler structure

B. ICD-10-CM provides greater specificity and detail

C. ICD-10-CM is less expensive to implement

D. ICD-10-CM is the older system

The preference for transitioning to ICD-10-CM over continuing with ICD-9-CM is primarily due to the greater specificity and detail that ICD-10-CM offers. This newer coding system allows for more precise coding of diagnoses and procedures, which is essential in capturing the complexities of modern healthcare. The increased number of codes in ICD-10-CM enables healthcare providers and researchers to document health conditions and treatments more accurately, leading to improved patient care and more effective health data collection and analysis. Furthermore, the detailed classification system facilitates improved communication among healthcare providers, insurers, and public health agencies, as it allows for the standardization of data reporting. This enhanced level of detail helps in identifying patterns, monitoring health trends, and conducting research that can contribute to better health outcomes. In contrast, ICD-9-CM had a limited number of codes and was insufficiently detailed to address many of the nuances found in current medical practice. Transitioning to a more robust and precise coding system like ICD-10-CM is vital for maintaining the quality and relevance of healthcare data in today's healthcare environment.

7. What impact does an incomplete reportability list have on casefinding?

A. It ensures all cases are reported

B. It has no effect on casefinding procedures

C. It could lead to underreporting of cases

D. It guarantees accurate data collection

An incomplete reportability list can significantly influence casefinding practices by potentially leading to the underreporting of cases. The reportability list serves as a comprehensive guide for tumor registrars, detailing all the conditions and cases that must be reported for surveillance and statistical purposes. When this list is incomplete, registrars may inadvertently overlook certain tumors or conditions that should be captured in the data collection process. This oversight can skew the overall cancer statistics, leading to inaccurate representations of cancer incidence and trends. Consequently, the healthcare community may miss crucial information on specific cancers or disease patterns, which can hinder public health efforts and research initiatives focused on prevention, treatment, and resource allocation. Thus, recognizing the impact of an incomplete reportability list is vital for ensuring accurate and comprehensive casefinding, underscoring its importance within the realm of cancer data collection and registry operations.

SAMPLE

8. What is commonly used to help determine treatment and prognosis for non-small cell lung cancer?

A. ALK gene rearrangements

B. BRAF mutation V600E

C. CD20

D. EGFR mutation analysis

In the context of non-small cell lung cancer (NSCLC), the determination of treatment and prognosis often relies on specific genetic mutations and alterations within the cancer cells. EGFR (epidermal growth factor receptor) mutation analysis is particularly significant in this regard. Patients with NSCLC who have certain mutations in the EGFR gene can benefit from targeted therapies known as tyrosine kinase inhibitors (TKIs). These therapies have been shown to be especially effective in patients with activating mutations in the EGFR, leading to improved outcomes and survival rates. Therefore, testing for these EGFR mutations is a standard practice that helps physicians tailor treatment plans that are more likely to be effective based on the genetic profile of the tumor. While other genetic alterations, such as ALK gene rearrangements and BRAF mutation V600E, also play roles in specific subsets of lung cancer patients, EGFR mutations are one of the most common and well-studied biomarkers in NSCLC for guiding treatment decisions. CD20, on the other hand, is primarily a marker used in lymphomas and is not relevant in the context of lung cancer treatment. Thus, the importance of EGFR mutation analysis in determining both treatment options and prognostic outcomes in NSCLC makes it the most

9. An important tumor identification field(s) is

A. Laterality

B. Vital status

C. Both (a) and (b)

D. Neither (a) nor (b)

Laterality is a crucial tumor identification field because it provides specific information about the side of the body where the tumor is located. This detail is important for treatment planning, prognosis, and understanding the tumor's biology. For example, tumors in paired organs (such as the lungs, breasts, or kidneys) may have different clinical implications based on laterality, affecting surgical decisions and radiation therapy planning. While vital status refers to whether a patient is alive or deceased, it is more relevant for survival analysis and patient follow-up rather than directly identifying tumors. Therefore, laterality stands out as the more significant and essential data point in the tumor identification process. Thus, focusing on laterality enhances the quality of tumor registries and supports better clinical decision-making.

SAMPLE

10. Reportable diagnoses made in utero are reportable if the:

A. Pregnancy results in a live birth.

B. Diagnosis was confirmed prior to birth and the disease is not evident at birth due to regression.

C. Both (a) and (b)

D. Neither (a) nor (b)

Diagnoses made in utero are reportable under specific circumstances that relate to how the pregnancy and subsequent birth event occurred. The correct choice indicates that both conditions must be met for the diagnosis to be reportable. When a pregnancy results in a live birth, this typically establishes the foundation for registry purposes since the individual is born and can be followed for cancer outcomes. Additionally, if the diagnosis was confirmed before birth and is not evident at birth due to regression, it indicates that even though the fetus had a diagnosis, the individual's health status may differ by the time of delivery, yet the condition deserves recognition in the registry due to its potential impact. Together, these conditions ensure that abnormal findings made during pregnancy that affect the child's health are properly documented, regardless of whether they are apparent at birth. This facilitates comprehensive tracking of cancer incidence and outcomes in this unique population, enhancing data accuracy for future research and trends in cancer. Thus, the reportability of diagnoses made in utero relies on the occurrence of a live birth and the confirmation of the diagnosis preceding birth, whether or not the condition remains evident at that time.

SAMPLE

Next Steps

Congratulations on reaching the final section of this guide. You've taken a meaningful step toward passing your certification exam and advancing your career.

As you continue preparing, remember that consistent practice, review, and self-reflection are key to success. Make time to revisit difficult topics, simulate exam conditions, and track your progress along the way.

If you need help, have suggestions, or want to share feedback, we'd love to hear from you. Reach out to our team at hello@examzify.com.

Or visit your dedicated course page for more study tools and resources:

https://seerctroperations.examzify.com

We wish you the very best on your exam journey. You've got this!

SAMPLE